Skip to main content

Breast cancer

Breast cancer

23-09-2021 | Oncology | News | Article

MONALEESA-2 update demonstrates ribociclib plus letrozole OS benefit

The final overall survival findings from the MONALEESA-2 trial confirm the long-term benefits of combining ribociclib with first-line letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.

21-09-2021 | Oncology | News | Article

Extended letrozole may improve long-term survival of early-stage breast cancer

Extending adjuvant aromatase inhibitor therapy with letrozole to 5 years improves survival among women with hormone receptor-positive breast cancer who have already received 2 to 3 years of tamoxifen, shows the phase 3 GIM4 trial.

18-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan shows ‘unprecedented efficacy’ in DESTINY-Breast03

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

17-09-2021 | Oncology | News | Article

BrighTNess update confirms benefit of adding carboplatin to neoadjuvant chemo in TNBC

Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

16-09-2021 | Oncology | News | Article

Residual cancer burden may predict treatment efficacy in breast cancer

Residual cancer burden offers prognostic information after neoadjuvant chemotherapy across breast cancer subtypes and treatments, show data from I-SPY2.

10-09-2021 | Oncology | News | Article

Surgery extent impacts long-term QoL in young breast cancer survivors

Young women who undergo mastectomy for breast cancer report poorer quality of life than those treated with breast conserving therapy more than 5 years after surgery, particularly when they also receive radiotherapy, research shows.

06-09-2021 | Oncology | News | Article

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

03-09-2021 | Oncology | News | Article

Cardioprotection worthwhile in anthracycline-treated breast cancer

Cardioprotective pharmacologic therapy may be effective against anthracycline-related subclinical heart damage in women with nonmetastatic breast cancer, with bisoprolol potentially offering greater benefits than ramipril, interim SAFE study data suggest.

27-08-2021 | Oncology | News | Article

PTSD not uncommon in cancer patients during COVID-19 pandemic

Around a fifth of people with cancer included in the French COVIPACT study reported symptoms consistent with post-traumatic stress disorder during the first national lockdown in response to the COVID-19 outbreak, find the investigators.

26-08-2021 | Oncology | News | Article

Definition of breast cancer HR-positivity questioned

HER2-negative breast tumors with low hormone receptor positivity could be treated similarly to triple-negative tumors, suggests research from Germany that showed similar survival outcomes between the two groups.

23-08-2021 | Oncology | News | Article

COVID-19-related drop in breast cancer screening may worsen pre-existing disparities

A US study has found that breast cancer screening rates declined during the COVID-19 pandemic, with the largest reductions among Black and Latinx women, which may exacerbate pre-existing disparities.

19-08-2021 | Oncology | News | Article

Similar outcomes with intermittent, continuous adjuvant letrozole in breast cancer

The final analysis of the SOLE trial has shown no significant difference in the outcomes of postmenopausal women with hormone receptor-positive breast cancer who received extended intermittent or continuous adjuvant letrozole.

16-08-2021 | Oncology | News | Article

Pan-cancer survival hope with individualized radiotherapy approach

Study findings suggest that using a genomic-adjusted radiation dose may help overcome the heterogeneity of tumor response to radiotherapy and improve overall survival for patients with cancer.

12-08-2021 | Oncology | News | Article

Genetic testing finds pathogenic variants among older breast cancer patients

Genetic testing should be expanded to include older women with breast cancer, especially those with triple-negative or estrogen receptor-negative disease, suggest US researchers.

11-08-2021 | Oncology | News | Article

Antibody response to COVID-19 vaccination appears durable in people with cancer

The seropositivity rate in response to the Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-2 remains high around 4 months after the second dose in cancer patients undergoing active therapy, report Israeli researchers.

09-08-2021 | Oncology | News | Article

Statins linked to improved TNBC survival

Statin use in the 12 months after diagnosis of early-stage triple-negative breast cancer is associated with improved survival in older women, findings indicate.

06-08-2021 | Oncology | News | Article

MHC-II expression may predict anti-PD-1 pathway response in HER2-negative breast cancer

A major histocompatibility complex-II tumor cell expression rate of 5% or more could identify HER2-negative breast cancer patients likely to benefit from the addition of PD-1 or PD-L1 inhibitors to standard neoadjuvant chemotherapy, research findings suggest.

03-08-2021 | Oncology | News | Article

Baseline PROs predict early endocrine therapy discontinuation in breast cancer

Patients with breast cancer may be at increased risk for early discontinuation of adjuvant endocrine therapy if they have depression, or poor physical or social wellbeing before treatment initiation, suggests a post-hoc analysis of the TAILORx trial.

30-07-2021 | Oncology | News | Article

FDA recommends pembrolizumab for high-risk, early-stage TNBC

Read more on this decision here

29-07-2021 | Oncology | News | Article

Extending adjuvant AI therapy by 2 years sufficient in postmenopausal breast cancer

The phase 3 SALSA trial has demonstrated no benefit of extending aromatase inhibitor therapy by 5 years versus 2 years in postmenopausal women with hormone receptor-positive breast cancer who have already received 5 years of adjuvant endocrine therapy.

Image Credits